Cancer Letters
Volume 172, Issue 2 , Pages 187-192, 30 October 2001

Cyclin D1 amplification correlates with early recurrence of squamous cell carcinoma of the tongue

Department of Otolaryngology, Keio University School of Medicine, 35 Shinanomachi Shinjuku, Tokyo 1608582, Japan

Received 30 May 2001; received in revised form 11 June 2001; accepted 18 June 2001.

Abstract 

Amplification of CCND1 was studied in 23 tongue carcinoma patients by fluorescence in situ hybridization (FISH) using a paraffin embedded specimen. All the patients received complete resection of the primary site with or without neck dissection. CCND1 amplification was positive in 13 (56.5%) out of 23 cases. Correlations between CCND1 amplification and histological grading, T category, N category, and Stages were not significant. The 5-year disease-free survival rate, which was 23.1% for CCND1 amplification positive patients and 80.0% for negative patients, was significantly better for the CCND1 amplification negative patients (P=0.0070). Nine patients were examined by dual-color FISH with the probe for centromere of chromosome 11 and 11q13. In five patients, who had positive amplification for CCND1, cell numbers with a larger number of signals for 11q13 than the centromere of chromosome 11 were significantly higher than those of CCND1 amplification negative patients (P=0.013). This indicates that amplification of 11q13 occurs more frequently than aberration of chromosome 11 in CCND1 amplification positive patients. From these results, the amplification of CCND1 is a key factor in predicting the aggressiveness of tongue cancer. Furthermore, FISH proved to be a useful method for such evaluation.

Keywords:  Tongue carcinoma, Early recurrence, Cyclin D1, Fluorescence in situ hybridization

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(01)00651-6

doi:10.1016/S0304-3835(01)00651-6

Cancer Letters
Volume 172, Issue 2 , Pages 187-192, 30 October 2001